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Abstract 
In 2003, the discovery of human amniotic fluid stem cells (hAFSC) initiated a new and very 
promising field in stem cell research [1, 2]. Prior to this, these cells were only used for 
prenatal diagnosis for detecting inherited defects in the unborn child. The cells within the 
amniotic fluid can be easily obtained by amniocentesis. Stem cells within the amniotic fluid 
are ckit positive [3] and harbor the potential to differentiate into cells of all three embryonic 
germ layers (entoderm, mesoderm and ectoderm). Compared to embryonic stem cells, no 
ethical issues arise because of the source of these cells. Other advantages are: low risk for 
tumor formation, self renewal, pluropotency and growth without the need of feeder layers. In 
2006, protocols were established for the differentiation of hAFSC into cells of neuronal, 
hepatic and osteogenic lineage [4]. The mechanistic target of Rapamycin (mTOR) is a 
pathway that regulates processes such as metabolism, cell cycle, proliferation, translation, 
ribosome biogenesis and nutrient transport. It consists at least of two complexes (mTORC1 
and mTORC2) which differ in their assembly and substrates. In our studies we focused on the 
differentiation potential of hAFSC into chondrocytes. These cells are involved in the 
development of avascular cartilage and long bones. In these processes several markers are 
activated (e.g.Sox9) to regulate the conversion from mesenchymal progenitor cells into 
chondrocytes. Additionally, chondrocytes produce an extracellular matrix composed of 
Collagens and Glycosaminoglycans. Worldwide more than 50% of people who are over 50 
years old suffer from degenerative diseases like osteoarthritis which is characterized by a loss 
of chondrocytes and their produced extracellular matrix. Generation of chondrocytes out off 
hAFSC could be an option to treat these diseases and to increase the life quality of patients. 
We successfully differentiated magnetic beat sorted monoclonal hAFSC via a pellet formation 
protocol into chondrocytes. Western blot analyzes and sulfated Glucosaminoglycan assays 
confirmed the generation of chondrocytes. The mTOR pathway plays an important role in this 
converting process. Western blotting for characteristic chondrogenic markers and 
Glycosaminoglycan measurements reveal that in the new generated chondrocytes the mTOR 
pathway is activated and that blocking of mTOR by its inhibitors influences the differentiation 
process.  
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Zusammenfassung 
Im Jahr 2003 schaffte die Entdeckung von Stammzellen im Fruchtwasser ein neues und sehr 
vielversprechendes Gebiet im Bereich der Stammzellenforschung[1, 2]. Vor dieser Zeit 
wurden diese Zellen nur innerhalb der Pränatal Diagnostik verwenden um vererbbare Defekte 
des ungeborenen Kindes aufzudecken. Die Zellen innerhalb des Fruchtwassers können leicht 
währen der Amniozentese gewonnen. Stammzellen innerhalb des Fruchtwassers sind ckit 
positiv [3] und  besitzen das Potential in Zellen aller drei Keimblätter zu differenzieren 
(Entoderm, Mesoderm und Ektoderm). Im Vergleich zu embryonalen Stammzellen gibt es 
keine ethischen Probleme bezüglich der Quelle dieser Zellen. Andere Vorteile sind ein 
geringes Risiko gegenüber Tumorbildung, Selbsterneuerung, Pluropotenzität und außerdem 
wachsen sie ohne „feeder layers“. 2006 wurden Protokolle erschaffen in denen 
Fruchtwasserstammzellen in neuronale, hepatische und osteogenische Zelllinien differenziert 
wurden konnten [4] . The mechanistic target of rapamcin (mTOR) ist ein Signalweg der 
Prozesse wie z.B. Stoffwechsel , Zellzyklus, Wachstum, Translation, Ribosombiogenese und 
den Transport von Nährstoffen reguliert. Er besteht zumindest aus zwei Komplexen 
(mTORC1 und mTORC2) welche sich in ihrer Zusammensetzung und ihren Substraten 
unterscheiden.  
In  unseren Studien konzentrierten wir uns auf das Differenzierungspotential von 
Fruchtwasserstammzellen in Chondrozyten. Diese Zellen sind an der Entwicklung 
vongefäßlose Knorpel oder lange Knochen beteiligt. In diesen  Schritten werden einige 
Marker aktiviert (z.B.Sox9) um die Umwandlung von   mesenchymalen Vorläuferzellen in 
Chondrozyten zu regulieren. Außerdem produzieren Chondrozyten eine extrazelluläre Matrix 
die aus Kollagenen und Glycosaminoglycanen zusammengesetzt ist. Weltweit leiden mehr als 
50% der Leute die über 50 Jahre alt sind an degenerativen Krankheiten wie Osteoarthritis 
welche durch einen Verlust an Chondrozyten und der von ihnen gebildeten extrazellulären 
Matrix gekennzeichnet ist.  Die Erschaffung von Chondrozyten aus Fruchtwasserstammzellen 
könnte eine Möglichkeit sein die Lebensqualität dieser Patienten zu erhöhen. Anhand einer 
Pelletbildung haben wir erfolgreich magnetisch-getrennte monoklonale 
Fruchtwasserstammzellen in Chondrozyten umgewandelt.  
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Western Blot Analysen und die Messung schwefelhaltiger Glycosaminoglycane bestätigten 
die Bildung von Chondrozyten. Der mTOR Signalweg hat eine wichtige Rolle in diesem 
Prozess. Western Blot Auswertungen charakteristischer Marker für Chondrozyten und 
Glycosaminoglycan Messungen zeigten auf, dass  mTOR in den neu erschaffenen 
Chonrozyten aktiviert ist und dass ein Blocken  des mTOR Weges durch seine Hemmstoffe  
den Differenzierungsprozess beeinflusst.                                                                                                                         
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1.Introduction 
 
1.1 Human amniotic fluid stem cells 
 
1.1.1 Pregnancy 
The human amnion is essential for the appropriate development of the fetus. Besides 
protection against infections, trauma,toxins and physical exposure it allows the fetus free 
movement within the uterus. 
The amnion and chorion surround the fetus and separates it from the maternal placenta.  
These extraembryonic tissues are important for the embryonic implantation, survival and 
development in utero[1]. The amnion forms the layer that is in contact with the amnion fluid. 
It consists mainly of an epithelial layer and connective tissue, which provides elasticity when 
the fetus grows and contains collagen, glycoproteins and laminins.  Next to the amnion lies 
the second fetal membrane, the chorion. It is build up by extraembryonic mesoderm and the 
two layers of the trophectoderm. The chorion ensures the transport of nutrients between the 
maternal and the fetal blood by its chorionic villi. 
 
Fig.1: Layers that wrap of the fetus in utero; encyclopedia2.thefreedictionary.com/pregnancy 
The decidua basalis, which is part of the maternal endometrium, completes the wrapping of 
the developing fetus. The composition of the amniotic fluid varies along time points of early 
stages. It mainly consists of ions and water which are transported across the chorioamniotic 
membranes. Proceeding gestation leads to a change of the compounds within the amniotic 
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fluid. The more the fetus grows the more organic materials are enriched in the fluid such as 
cells from fetal skin, fetal respiratory, urine and gut tissue [5]. These cells are analyzed during 
routine prenatal diagnosis via amniocentesis. 
1.1.2 Prenatal diagnosis 
For prenatal diagnosis the amniotic fluid is collected by ultrasound transabdominal puncture. 
Only some milliliters of this fluid iare sufficient to determine if the fetus carries any 
chromosomal abnormalities caused my mutations or chromosomal aberrations. In this way 
e.g. Down Syndrome, which is characterized by an additional chromosome 21, can be 
discovered. 
 
Fig.2: Process of amniocentesis for prenatal diagnosis; www.bing.com/.../Amniocentesis?q=amniocentesis 
In addition to amniocentesis, that can be carried out between week 15 and 18 of pregnancy, 
biopsy of chorionic villi (10. week of pregnancy) and cordozentesis (20. week of pregnancy) 
are common procedures for prenatal diagnosis.                                                                  
Prenatal diagnosis is also able to reveal genetic diseases for which treatment options are 
available. Some diseases can be directly cured in utero, e.g. the genetic disease Hypothreosis 
is characterized by a lack of a thyroid hormone which can lead to mental retardation in early 
infany. This can be prevented by Thyroxin injections during pregnancy. Prenatal diagnosis 
helps parents to adjust to the fact that their unborn child has a genetic disease. It facilitates the 
management of medical procedures during birth, but also gives the parents the opportunity to 
undertake an abortion.  
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1.1.3 Human amniotic fluid stem cells 
In addition to the use in amniocentesis in prenatal diagnosis, human amniotic fluid reveals 
mayn potentials. It contains cells with the properties of pluripotent stem cells as characterized 
by their marker expression profile (expression of ckit, Oct4, SSEA4 and Nanog), self renewal, 
proliferation, Teleomerase activity and differentiation potential. These cells are termed human 
amniotic fluid stem cells (hAFSC) and are the focus of our studies. Because these cells can be 
easily obtained by amniocentesis, no ethical concern arises in contrast to embryonic stem cells 
which are derived from the inner cell mass of the blastocyste. Furthermore hAFSC do not 
form tumors in serve combined immunodeficient mice.  Moreover they grow without need of 
feeders  and they can carry out 250 population doublings without losing their stable 
karyotype. The presence of a Y chromosome in the cells of the fluid sample from a mother, 
who was pregnant with a boy, reveals that the cells within the amniotic fluid derive from the 
fetus and not from the mother. 
 hAFSC Embryonic 
stem cels 
Induced Pluripoten 
stem cells 
Mesenchym
al stem cells 
Source Amniotic fluid Early stage 
embryo 
Somatic cells Bone marrow 
and other 
adult tissues 
Feeders Not required Required Required Not required 
Markers SSEA4,ckit SSEA3/4,   
Tra1-60/1-81 
SSEA3/4,   Tra1-
60/1-81 
CD73, CD90, 
CD105 
Plasticity Broadly 
multipotent 
Pluripotent Pluripotent Multipotent 
Tumorgenesis No Yes Yes No 
Lifespan in vitro Long Long Long Short 
Ethical issues No Yes No No 
Fig.3: Comparison of stem cell populations; adopted from [6] 
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To separate the stem cells from the rest of the cells within the amniotic fluid, hAFSC can be 
isolated via magnetic microspheres directed against the surface antigen ckit (CD117).  This 
receptor for stem cell factor [7] is important for gametogenesis, melanogenesis and 
hematopoiesis [8, 9]. Subsequent, single cell cloning serves to show that from a single cell 
differentiation into adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic 
lineage can be carried out. 
In an amniotic fluid sample, obtained during amniocentesis, only 1% of all cells are Oct-4 
positive [5]. Oct -4 is a marker specific for pluripotent stem cells known to be expressed in 
embryonic carcinoma cells, embryonic germ cells, and embryonic stem cells [1]. It is 
localized in the nucleus and is expressed when stem cells are in an undifferentiated state. 
When differentiation starts Oct-4 is downregulated. Hence Oct-4 seems to maintain 
pluripotency. Besides Oct-4, cells in the amniotic fluid express cylin A[10], a marker of 
proliferation [11], various mesenchymal, neuronal and stage specific embryonic antigen 
markers but no hematopoietic markers (Fig.4). 
Markers  
Oct 4 Pluripotent stem cells 
Cyclin A Proliferation marker 
CD90, CD105,CD73,CD166,CD29,CD44, 
HLA-ABC,SH2,SH3,SH4, 
Mesenchymal markers 
 
CD133 Neuronal stem and progenitor cells 
Nestin Neuronal progenitor cells 
CD117 (ckit) Receptor for stem cell factor 
SSEA-4 Stage specific embryonic antigen  
Vimentin Stem cell factor, in ectodermal, neural and 
pancreatic progenitor cells 
Negative for CD45,CD34, CD14 Hematopoietic marker 
Fig.4: Markers expressed in hAFSC [1, 4, 5, 10]. 
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Another characteristic of pluripotent hAFSC is the activity of the telomerase enzyme which is 
also present in embryonic tissues and germ cells but not in non-transformed somatic cells. The 
enzyme protects the ends of chromosomes from degradation and is a marker for pluripotent 
and proliferating cells [2]. 
The spontaneous formation of three dimensional aggregates, so called embryoid bodies,  
without addition of antidifferentiation factors is a further phenomena occurring in amniotic 
fluid cells that was only observed in embryonic stem cells before[3]. These multicellular 
aggregates allow an insight in the molecular mechanisms of cell differentiation during early 
mammalian embryogenesis[12]. Human amniotic fluid stem cells express markers which are 
characteristic for the undifferentiated state, like Oct-4 and nanog. When the formation into 
embryoid bodies starts, these markers disappear and lineage specific markers, such as Pax 6 
(ectodermal), nestin (ectodermal), Flk1 (endothelial), E-cadherin (epithelial) , GATA 4 ( 
endodermal), T ( brachyury; mesodermal) and HBE1 (mesodermal), appear [9]. 
For new therapeutic concepts and tissue engineering the most important property is the 
differentiation of hAFSC into cells of all three embryonic germ layers ( mesoderm,ectoderm, 
endoderm ) including cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and 
hepatic lineages [4].In 2006, Atala et al. established protocols for the differentiation of 
hAFSC into neuronal ( representing ectoderm), hepatic ( representing endoderm) and 
osteogenic lineage ( representing mesoderm) [5]. The successful differentiation was proven 
by RT-PCR of specific markers and the functionality of the three lineages was assessed. For 
example: differentiated hAFSC were cultured in osteogenic media and afterwards they were 
transplanted  in an alignate/collagen scaffold [13].After 45 days these constructs produced 
mineralized calcium which could be demonstrated by Alizarin red S staining. The same 
experiment was established in vivo. Again transplanted human AFS cell/ scaffold constructs 
were grown in osteogenic media for one week and afterwards transferred into 
immunodeficient mice. As control, an unseeded scaffold was implanted into other mice. After 
8 weeks mineralized tissue could be derived from the mice with the cell-seeded scaffold 
whereas the control group did not show evidence of mineralization. After 18 weeks bone 
material could be observed [5].  
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In summary, human amniotic fluid cells can be seen as an intermediate between lineage- 
restricted adult progenitor cells and embryonic stem cells. Atala´s experiments exhibited the 
differentiation potential of hAFSC into cells of all three germ layers which was a 
breakthrough in stem cell research. These findings allow new approaches in tissue 
engineering and other options for the treatment of various human genetic diseases in the 
future.  
 
              Fig.5: Overview of the use of hAFSC 
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1.2 mechanistic Target of Rapamycin  
The mechanistic target of Rapamycin (mTOR) belongs to the phosphatidylinositol 3-
kinase related family and phosphorylates serine and threonine residues on target 
proteins[14]. It is involved in a variety of regulatory processes in the cell such as growth 
regulation, proliferation control, regulation of ribosome biogenesis, autophagy, 
transcription, translation and cancer cell metabolism[15]. Additionally, mTOR functions 
in cell growth and division and is an important drug target in cancer[13]. 
mTOR consist in at least two complexes, mTORC1 and mTORC2. mTORC1 includes 
mTOR protein, raptor (regulates mTORC1 by acting as a scaffold that recruits mTORC1 
specific substrates) and mLST8, mTORC2 contains mTOR, mLST8, rictor (rapamycin-
insensitive companion of mTOR) and sin1( stress activated protein kinase interacting 
protein). The two complexes differ only in raptor (mTORC1) and rictor and sin1 
(mTORC2). They can also be distinguished by their substrates downstream and regulatory 
mechanisms upstream see Fig.6. Activated mTORC1 phosphorylates 70S6K ( ribosomal 
70S6 kinase) at T389 which is followed by phosphorylation and activation of S6protein at 
S240/244 and activation of 4EBP1( eukaryotic initiation factor 4E binding protein-1). 
This activation subsequently leads to the initiation of proteintranslation. mTORC2 has Akt     
(= protein kinase B) as its main substrate that is phosphorylated at S473. Additional 
phosphorylation at T308 by PDK-1 ( phosphoinositide-dependent kinase 1) fully activates 
Akt [16, 17].  
Upstream of the two complexes resides the TSC1/TSC2 complex which encodes for 
hamartin and tuberin. Mutations in this complex can be found in the disease called 
tuberous sclerosis. PI3K (phosphatidylinositol-3 kinase) gets activated by binding of a 
specific molecule to the insulin receptor substrate 1 (IRS1). PDK1 together with Akt bind 
to PIP2 at the plasma membrane, and PDK1 phosphorylates Akt at T308. Akt-mediated 
phosphorylation on S939 and T1492 leads to a downregulation of the GTPase activity of 
tuberin, which is encoded by the TSC2 protein complex, towards Rheb ( Ras homolog). 
Rheb regulates mTOR via FKBP38 which binds to this complex and leads to an 
inactivation. Rheb binds to FKBP38 and blocks its attachment to mTOR[14]. The mTOR 
pathway is also regulated over a negative feedback loop. Active mTORC1 substrate S6K 
has the potential to block IRS1 and according to this the mTOR pathway is silenced. 
Contrarily, treatment with the mTORC1 inhibitor Rapamycin abolishes the blocking of 
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IRS1 which can now activate mTORC2 and following to this Akt is phosphorylated at 
S473. This negative feedback loop explains why the mTORC2 is activated whereas 
mTORC1 is blocked by Rapamycin. In 2007, Tremblay et al. demonstrated that this 
regulation is due to the ability of S6K to phosphorylate IRS1 at S1101 [18]. This 
phosphorylation presents an inhibitory signal of the IRS-1 function, is increased upon 
nutrient overload and leads to a phenomena called insulin resistance. The latter is due to 
the restricted potential of insulin to control downstream metabolic actions [19]. 
 
 
Fig.6: mTOR signalling pathway 
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1.3 Chondrocytes 
 
1.3.1.Development of chondrocytes 
. 
The development of chondrocytes includes various steps in which the cells change their 
morphology and their marker expression pattern. It is important to distinguish between 
chondrocytes that form articular cartilage in adults and those who generate long bonesduring 
infancy.  
Chondrocytes have their origin in mesenchymal cellas. During growth chondrocytes generates 
long bones via endochrondral ossification. The epiphyseal growth plate, located at the end of 
long bones, consists of resting and proliferating chondrocytes which have the ability to form a 
cartilagous matrix. Towards the middle of the long bone progenitor cells condense and 
enlarge their cytoplasmatic volume to differentiate into pre hypertrophic cells and afterwards 
into hypertrophic chondrocytes. The increase of volume is due to the activation of the 
mechanistic target of Rapamycin (mTOR) which regulats ribosome biogenesis, cell size and 
protein synthesis [20]. During these steps no type II collagen is expressed whereas type X 
collagen production arises in the hypertrophic chondrocytes. Furthermore the cells change 
their morphology from flat to round chondrocytes. With the induction of type X collagen a 
calcified matrix can be generated. After the development of mineralized extracellular matrix, 
hypertrophic chondrocytes differentiate into terminally mature chondrocytes which undergo 
apoptosis. Before this step, a bone collar is formed around the hypertrophic cells, which 
attracts osteoblast progenitors through its blood vessels, which different into mature 
osteoblasts. In addition, the blood vessels also carry osteoclast progenitors. These cells 
reabsorb the mineralized matrix so that bone remodeling can be carried out [21]. 
 
Fig.7: Development and marker expression of chondrocytes. 
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1.3.2 Marker expression of chondrocytes 
 
Sox 9: Sox 9 belongs to the SOX (Sry-related high mobility group box) family. It is a 
transcription factor that has the high mobility group (HMG) DNA binding motif in common 
with the mammalian testis determining factor Sry [22]. Sox 9 expression occurs in progenitor 
cells such as chondroprogenitors, osteoprogenitors and preadipocyts [23] but Sox 9 
expression lacks in differentiated cells except chondrocytes. Sox 9 is expressed in 
mesenchymal progenitor cells, round and flat chondrocytes and assures the differentiation 
process of mesenchymal progenitor cells into chondrocytes. Furthermore, expression of Sox 9 
prevents chondrocyte´s hypertrophy. Ikegami et al. studied the role of Sox 9 in chondrocyte 
development via Sox 9 knock down experiments [22]. One the one hand, the knock down of 
Sox 9 in round chondrocytes leads to a loss of Collagen Type 2a1 and apoptosis, on the other 
hand, knock out of the same transcription factor but this time in flat chondrocytes brings 
immediately terminal maturation without hypertrophy and with excessive apoptosis. If Sox 9 
is absent in mesenchymal progenitor cells no mesenchymal condensation and cartilage 
formation occurs. Contrary, overexpression of Sox 9 leads to a delay in cartilage 
mineralization and misexpression at the stage of hypertrophic chondrocytes gives raise to  
missing bone indicating that Sox 9 is a negative regulator of cartilage vascularization [24] and 
therefore also of hypertrophy. 
Sox 9 is a target bur also acts through the mTOR signaling pathway. This transcription factor 
binds to the promoter of the PI3 kinase subunit PI3kca which leads to increased 
phosphorylation of Akt. This activation of Akt promotes chondrocyte survival and prevents 
hypertrophy [22].   
 
Proteoglycan: Extracellular matrix is composed of collagen and proteoglycans. 
Proteoglycans consist of a core protein and covalently bound sulfated glycosaminoglycans 
(sGAG) and are the main components of the extracellular matrix. Depending on the linked 
glycosaminoglycans, four types of proteoglycans can be distinguished. 
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Glycosaminoglycan chain Core Protein 
Chondroitin sulfate Aggrecan, Neurocan,  
Dermatan sulfate Versican, Decorin, Biglycan 
Chondroitin sulfate Perlecan, Testican 
Keratan sulfate Fibromodulin, Lumican 
Fig.8: Overview of Proteoglyantypes ; http://en.wikipedia.org/wiki/Proteoglycan 
                           
Within these four types, aggrecan is the major basis for proteoglycan in cartilage. Together 
with type II collagen it forms the articular cartilage, an elastic interaction of collagen fibers 
which connect the proteoglycan aggrecan. Aggrecan is build up of two globular domains at 
the N- and C- terminal end and glycosaminoglycans divide those two ends. 
A main regulator of proteinglycan synthesis is mTOR [25]. The major inducer of this 
signaling pathway is insulin growth factor 1 (IGF1). IGF is crucial growth factor for the fetal 
and postnatal development and regulates the organ size during gestation and of the growing 
child after birth. The binding of this growth factor at the insulin receptor substrate (IRS1) 
leads to activation of PI3 kinase that phosphorylates and activates Akt. Following this, the 
mTOR pathway is activated and since this pathway is necessary for ribosome biogenesis and 
protein transaltion, proteoglycan synthesis is also induced. 
The dependence of mTOR in the poteoglycan synthesis was evidenced by Starkman et.al in 
2005 [25]. Inhibitation of Akt with the inhibitors Ly294002 or Wortmanin blocks the 
phosphorylation of Akt and consequently inhibits the activation of the downstream mTor 
cascade. If Akt is constitutively activated the synthesis is strongly enhanced compared to the 
expression of dominant negative Akt that causes inhibition of proteoglycan production [26].                 
In addition, proteoglycan assays demonstrate that, with the addition of IGF-1, the 
incorporation of radiolabeled sulphate increases to 150% compared with control groups 
without IGF-1. 
The ability of IGF-1 to enhance matrix synthesis is reduced in aged cartilage and in the 
cartilage of  people who suffer from the disease osteoarthrits ( OA). Reactive oxygen species 
can interfere with the IGF-1 stimulated cascade and leads to an IGF-1 resistance [26]. The 
main factor of this process is the phospohorylation site of IRS-1. In normal human 
chondrocytes, IGF-1 induces phosphorylation of IRS-1 at Tyr 612 and of Akt at Ser 473. This 
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activation causes activation of the following mTOR pathway and generation of cartilage 
matrix. If  IRS-1 gets phophorylated at Ser 312 or Ser 616, the stimulating function of IRS-1 
is blocked and according to this also the synthesis of cartilage. 
The phosphorylation of the inhibitory sites of IRS-1can also be observed when normal human 
chondrocytes are exposed to tert-butylhydroperoxidase (tBHP). This molecule is a substrate 
for glutathione and causes oxidative stress. On the other hand, exposure of chondrocytes 
isolated from osteoarthritic cartilage with antioxidants activates stimulating phosphorylation 
of IRS-1 at Tyr 612 and of Akt at Ser 473. These studies reveal that, depending on the 
presence of endogenous reactive oxygen species (ROS) due to oxidative stress, the 
phosphorylation pattern of the IRS-1 residues determines if the mTOR pathway and 
continuatively cartilage synthesis is activated or not.  
 
Collagen: Collagen is a protein that makes up almost 40 % of all the proteins that can be 
found in the human body. Connective tissue mainly consists of collagen that forms fibrins 
which give this tissue its elasticity. There are 28 types of collagens which can be 
distinguished by their appearance in the body.  Collagen type II is the main component in 
cartilage and a crucial marker for chondrocytes. Its expression depends on various 
endogenous circumstances such as hypoxia [27] and the nutrient state of the cell.  
 
 
 
 
Marker of chondrocytes that form 
articular cartilage 
 
Sox 9, 5,6 Involved in the differentiation of 
mesenchymal progenitor cells into 
chondrocytes and formation of extracellular 
matrix, regulated my FGF signalling 
Type II collagen Important marker in cartilage 
Proteoglycan ( Glucosaminoglycan) Compound of extracellular matrix of 
chondrocytes 
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Marker of hypertrophic 
chondrocytes that form long bones 
 
Indian hedgehog (Ihh) Expressed by pre-hypertrophic chondrocytes. 
Ihh is a regulator for the proliferating 
chondrocytes and for the formation of the 
bone collar through activating the expression 
of parathyroid hormone related protein 
(PTHrP). 
Parathyroid hormone related protein (PTHrP) Important for the hypertrophic development 
Type X collagen Marker for chondrocyte maturation and 
hypertrophy 
Alkaline Phosphatase Expressed during chondrocyte development 
and has highest level in hypertrophic 
chondrocytes  
Runx Transcription factor 
 
Fig.9: Marker expression in chondrocytes 
 
1.3.3. The mTOR pathway in chondrocytes 
 
As discussed in 1.2 mechanistic target of Rapamycin, (mTOR) works as a nutrient sensing 
kinase and enhances bone growth in response to insulin. Consequently, addition of the 
inhibitor Rapamycin leads to the opposite effect. This potent inhibitor also affects the 
proteoclycan synthesis, type X collagen expression and the expression of Indian Hedgehog     
(Ihh), a crucial regulator of chondrocyte differentiation in long bones [20]. As regulator of 
ribosome biogenesis, protein synthesis and nutrient transport, mTOR determinates the size of 
the cells as well as the intake of essential nutrients, e.g. amino acids. Rapamycin is able to 
reverse the effects of insulin when added to the insulin containing media. If the media 
contains Rapamycin alone, the cells are unaffected. Insulin can induce bone growth, 
chondrocyte proliferation, enlargement of the growth plate and it can stimulate the total bone 
length occupied by the hypertrophic zone [20]. To study the impacts of insulin and 
accordingly Rapamycin on mTOR the staining of PS6, a substrate of mTOR, was observed. 
The treatment with insulin leads to a strong signal whereas addition of Rapamycin leads to an 
abolishment. 
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Rapamycin has the feature to mediate anti-angionic processes which leads to a control of the 
tumor growth through the decrease of vascular endothelial growth factor expression [28]. 
Inhibition of the mTOR pathway by Rapamycin has a crucial impact on the chondrocyte 
development. A decrease in the function of osteoclasts, bone resorption, osteoblast 
proliferation and an increase in osteoblast differentiation are the consequences in bones 
treated with Rapamycin [29, 30]. 
Another study in 2009 demonstrated, that Akt is a potent regulator for the four cellular 
processes of chondrocyte maturation, proliferation, cartilage matrix production and cell 
growth in skeletal development [31]. Compared to dominant negative Akt ( dn Akt),  myc Akt 
( Akt is constitutively activated) triggers the phophorylation of the S6 protein as well as the 
endochondral ossification. 
Nowadays, Rapamycin is used as an immunosuppressant to avoid allograft rejection. This 
characteristic is based upon the anti-proliferative and anti-angiogenic qualities of Rapamycin. 
mTOR also plays an important role as a nutrient sensor especially when IGF1                          
( insulin-growth factor 1) binds to the IRS-1, which leads to the activation of PI3K that 
phosphorylates and activates Akt. PI3K mediated Akt phosphorlation is assumed to the 
induction of the proteoglycan synthesis which is a marker of chondrocytes. In addition, 
phosphorylated Akt activates p70S6k and therefore induces cell survival. Blocking of PI3K 
by its inhibitors Wortmanin and LY294002 causes lack in Akt phosphorylation and a block in 
proteoglycan synthesis. Treatment with Rapamycin, which is an inhibitor of mTOR, leads to a 
decrease in Akt phosphorylation and proteoglycan synthesis [25]. 
The sensing of insulin by mTOR also leads to an induction of bone growth, chondrocyte 
proliferation, total bone length occupied by the hypertrophic zone and to an enlargement of 
the growth plate. These effects can be reversed by the addition of Rapamycin into the media 
of the growing chondrocytes [20]. 
Induction of autophagy is a process in which the cell can adapt to a low energy and nutrient 
status by degradation of the cell´s own properties. The AMP activated protein kinase (AMPK) 
and mTOR play the key roles in autophagy. AMPK functions as an energy sensor and gets 
activated when AMP ( adenosinemonophosphate) binds to this kinase. According to this, 
AMPK stimulates catabolic pathways which produce ATP, and inhibits energy-consuming 
anabolic pathways. Activation of AMPK inhibits mTOR dependent signals [32] which can be 
proven by silencing of AMPK by AMPK specific siRNA. In these AMPK silenced cells the 
levels of phosphorylated mTOR and p70S6K is increased. According to this, mTOR 
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suppresses autophagy by its ability to regulate ribosome biogenesis and translation. AMPK is 
required for the induction of autophagy and its suppression results in the stimulation of 
survival signaling and suppression of apoptosis [33]. 
 
1.3.4.Influence of hypoxia on chondrocytes 
 
Exposure of human articular chondrocytes to 1% oxygen (hypoxia) compared to 20% oxygen 
( normoxia) has a significant effect on the expression of various chondrocyte specific markers 
such as Sox 9,  Collagen 2A1 and Collagen 9A1 [27]. Because cartilage is an avascular tissue 
with reduced access to oxygen and nutrients, experiments within a low oxygen environment 
assure comparable results to the processes in vivo.  
The two hypoxia– inducible factors HIF -1α and HIF - 2α mediate the effects of hypoxia but 
in contrast to the knock down of HIF -2α by HIF-2α specific siRNA, the abolishment of           
HIF-1α through its specific siRNA does not show any effects on the expression of Collagen 
2A1, Collagen 9A1 mRNA and Sox 9 expression [27]. The fact that the deletion of HIF-2α 
leads to a reversal of the hypoxia induced marker expressions demonstrates that HIF-2α is the 
key regulator for the hypoxic induction of the cartilage genes (Collagen 2A1 and        
Collagen 9A1) and Sox9 in human articular chondrocytes. 
Under normal conditions (20% oxygen), HIF-1α gets hydroxylated on its proline residues and 
ubiquitinated via the interaction with the van Hippel-Lindau tumor suppressor protein pVHL. 
Because ofthis attached ubiquitination, the proteosome targets HIF-1α for degradation. In 
contrast to this, in a hypoxic environment, the activity of the HIF-1α targeting prolyl 
hydroxylases in suppressed and following to this no hydxroxylation and no degeneration by 
the proteosome takes place. HIF-1α can translocate into the nucleus and generate a 
heterodimer with HIF-1β. The transcription gets activated when this heterodimer attaches to 
the hypoxia-responsive elements (HREs) which are located in the promoter region of the 
hypoxia- inducible genes. HIF-1α and HIF-2α are closely related but the decision which of 
these two factors is activated depends on the cell type [27, 34].  
The expression of Sox 9 is necessary for the two collagen types Collagen 2A1 and       
Collagen 9A1. Under normoxia conditions, knock down of Sox 9 via Sox 9 specific siRNA 
leads to a decrease of the levels of the Collagen 2A1 and Collagen 9A1 , whereas no effect 
was observed at the levels of Collagen 1A2 expression. Exposure to hypoxia increases the 
expression of Collagen 2A1 and Collagen 9A1. However, this effect cannot be observed when 
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Sox 9 was depleted. These results demonstrate, that Sox 9 is crucial for the expression of 
Collagen 2A1 and Collagen 9A1 rather than hypoxia [27]. 
 
Fig.10: Regulation of the hypoxia-inducible factors concerning the expression of chondrocyte matrix genes [27]. 
 
Besides its ability to mediate the effects of exposure to 1% oxygen, hypoxia inducible factor-1 
(HIF-1) mediates a process called autophagy. Its main function is maintaining the balance 
between the production and degeneration of products.  
 
Fig.11:Overview over the autophagic process: www.abcam.com/ps/cms/Images/Autophagic_Pathway_480px.jpg 
 
Damaged organelles and unused proteins get wrapped by a double membrane and form the so 
called autophagosome. Next, the membrane of the autophagosome attaches to the membrane 
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of the lysosome and following to that, the autophgosome and the lysosome fuse together and 
generate the autophagosome in which the degeneration of the cell´s contents takes place.    
HIF-1 can either directly activate autophgay or via the activation of the AMP activated 
Protein Kinase (AMPK). This kinase has the ability to respond to various nutrient signals       
(e.g. hypoxia) and gets activated when AMP binds and at the same time phosphorylates the 
kinase. This activation is dependent on the current energy status of the cell. A decrease of 
nutrients within the cell leads to a decrease of ATP. This in turn leads to an increase of AMP 
and following to that to an enhanced activation of AMPK. mTOR plays the antagonist of 
AMPK in the control of autophagy. It inhibits the autophagic process because of its ability to 
induce protein synthesis and transcription, and consequently no cellular components have to 
be degraded at low energy states. The discrepancy between mTOR and AMPK can be proven 
by AMPK specific siRNA treatment. Kockdown of AMPK leads to an activation of mTOR  
( demonstrated by detection of phosphorylated total mTOR and phosphorylated S6 kinase) 
and subsequent to inhibitation of autophagy [33]. 
 
 
Fig.12: Regulation  of autophagy [33]. 
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1.3.5 Diseases 
 
Osteoarthritis is one of the most common degenerative disease which includes damage of 
articular cartilage and subchondral bone (http://en.wikipedia.org/wiki/Osteoarthritis). 
Worldwide more than 10% under 15 years and more than 50% over 50 years suffer from this 
joint and bone degenerative disease. There are many types of arthritis and the most common 
are non inflammatory osteoarthritis and inflammatory rheumatoid arthritis [21]. These 
diseases contribute to affection in the quality of life and decrease in daily procedures such as 
walking, running and standing.   
Symptoms of these degenerative diseases are often pain when moving or a noise when the 
affected joint is moved. The treatment of these chronic diseases is difficult due to the limited 
capacity of these tissues for self renewal [35] 
In the past, people who suffered from degenerative joint disease could only be cured by 
surgical joint replacement or bone grafting but within this processes the ability of a transplant 
rejection existed. Because of that, autologous cells were used but the capacity of these cells is 
very limited. Therefore stem cell therapies are the current focus regarding the treatment of 
degenerative joint and bone diseases. For this purpose a cell source that is easily accessible, 
that can expand in large numbers and that has a chondrogenic potential has to be found [36]. 
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2.Materials and Methods 
 
2.1 Basic cell culture techniques 
2.1.1 Thawing of cells 
 Thaw the frozen cells from the freezing tube in a water bath at room temperature 
 Add 2 milliliters of the specific media to a 15 milliliter Falcon tube 
 Add the cells to the Falcon tube 
 Centrifuge for 5 minutes at 1500 rmp 
 Discard the supernatant and resuspend the pellet in 2ml of a certain media 
 Plate the cells on a 6 cm dish 
 2.1.2 Freezing of cells 
 Suck off the old media 
 Wash the cells with 1xPBS 
 Discard the PBS 
 Add Trypsin to the cells 
 Add the appropriate media when cells detach of the plate 
 Add certain amount of media depending on the size of the plate 
 Collect the cells in a 15ml Falcon tube 
 Centrifuge the cells for 4 minutes at 1300 rpm 
 Discard the supernatant and resuspend the pellet in media and add 10% DMSO in a 
ratio 1:10 
 Aliquote the cells in 1 ml freezing tubes. 
 Store the tubes at -80 °C and later at -273°C  
 
 
 
 
28 
 
2.1.3 Passaging of cells 
 Discard the old media and wash the cells with 1x PBS 
 Suck off the PBS and trypsinize the cells 
 Add media in the ratio the cells should be splitted ( e.g. add 3 ml media when the cells 
should be splitted 1:3 and transfer 1 ml in the new dish) 
 Fill up the media to an appropriate amount 
 
 96 well 24 well 12 well 6 well 6 cm dish 10 cm dish 
Trypsin μl 10 30 50 70 200 1000 
Media μl 100 500 1000 1500 2000 8000 
 
2.2 Cell lines 
2.2.1 Novel patient-derived amniotic fluid stem cells 
Cells are obtained from Dr.med Joo Gabor after the patients gave their informant consent to 
use the amniotic fluid cells. Ethics Committee approved studies.These cells grow in chang 
media and can be passaged without any spontaneous differentiation over higher passages. In 
immunofluorescence analyzes, these cells express stem cells factors such as SSEA4 and Oct 4 
at a moderate level. 
2.2.2. CD117 single cell clones 
Via magnetic beat sorting, cells which express the stem cell receptor CD117 are selected from 
the other cells in the amniotic fluid. These cells are termed CD117 cells grow in chang media 
without any need of feeder layers and with a stable karyotype. The cells were obtained via 
amniocentesis and healthy children were born. Based on these cells, single cell clones are 
generated by single cell dilution (see. Materials: 2.5: Single cell dilution). Cells are 
characterized according to their maker expression pattern, cell size, nucleus size, cell circle 
distribution and their growth rate. The single cells clones are termed A-P. After some weeks, 
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some of the clones stopped growing or had a humble marker expression pattern and for this 
reason, two groups including six single cell clones are created. The cells within these groups 
share similar properties when focus on the qualities mentioned above.  
 
2.3 Media  
2.3.1 Chang media 
 80 ml alpha-MEM 
 18 ml Chang B 
 2ml Chang C 
 15 ml Hyclone Serum 
 1ml Glutamine 
 1 ml Penicillin/ Streptomycin 
 
2.3.2 Chondrogenic differentiation media 
 DMEM media 
 10% FCS or 0% FCS 
 ITS (1:1000) 
 Dexamethasone (1:1000) 
 Ascorbic acid (1:1000) 
 Non-essential amino acids (1:100) 
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2.4 Casy measurement 
 Remove old media 
 Wash cells with 1xPBS 
 Trypsinize the cells 
 Stop trypsin with an appropriate amount of media 
 Add 10µl of the cells in the media into 5 ml of Casy ton 
 Measure the amount of cells within 1 ml or determine the size of one cell  
 
2.5 Single cell dilution 
 Same procedure as Casy measurement ( see 2.4.Casy measurement) 
 With the result of the number of cells within 1ml it can be calculated how many micro 
liters  are needed so that one cell is plated in one 96 well and grow as a single cell 
 
2.6  Pellet formation for chondrogenic differentiation 
 Grow cells to 70-90 % confluency in a 10 cm dish 
 Wash cells with 1xPBS 
 Discard the 1xPBS 
 Trypsinize the cells 
 Stop the trypsine with e.g. 5 ml chondrogenic differentiation media +10% FCS 
 Transfer the cells in to a 15 ml Falcon tube 
 count the cells via Casy ( see Materials and Methods: 2.4: Casy count) 
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 Centrifuge the cells in the Falcon for 4 minutes at 1300 rpm 
 Wash the cells with 1x PBS and centrifugate them  
 Multiple the result from the Casy count with the amount of media in the Falcon            
( e.g.5 ml) and calculate how much media is needed that 100µl media contain 250 000 
cells  
 Add the calculated amount of media but this time use chondrogenic media + 0% FCS 
 If any additional chemicals (e.g.inhibitors) are added, calculate how much of the 
substance is needed for all the concerned wells. Add them separately in an adequate 
amount of media and put 100 μl of this mixture in each 96 well 
 Transfer 100μl of the resuspended cells in one well of a 96 well plate 
 Centrifuge the 96 well plate at 1000rpm for 10 minutes 
 Incubate the cells at 37 °C and 5% CO₂  
 
Fig.13: Pellets in 96 round bottom well 
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2.6.1 Lysis of chondrocyte pellets 
 Put the 96 well on ice 
 Remove the old media and wash the cells one time with 100 µl 1xPBs 
 Incubate the cells with 20 µl NP40 lysis buffer (450µl NP40 buffer + 5µl Pim +       
5µl PMSF) 
 After 20 minutes the pellets are dissolved 
 Put the protein lysates into Eppendorf tubes and shock freeze them in liquid nitrogen 
 Thaw the samples, vortex them and shock freeze them again 
 After the samples thawed leave them on ice for 20 minutes 
 Centrifuge them for 20 minutes full speed at 4 °C 
 Store the supernatant at -80°C           
 Following procedure see Western Blot 
 
2.7 Analytic methods 
2.7.1 Immunofluorescence 
 Cells are cultured in 24 wells or 2 well glass slides 
 Discard the media 
 Wash the cells three times with 1ml 1xPBS 
 Fix the cells either with 1ml 4% Formaldehyde or a 1:2 Aceton/Methanol mixture for 
20 minutes 
 Wash the cells three times with 1ml 1xPBS 
 Incubate the cells with 150μl  Tween 20 or Triton x100 for 5 minutes 
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 Wash the cells three times with 1ml 1xPBS 
 For the blocking step, add 1ml 1% BSA  
 After this 20 minutes get rid of the 1% BSA and add 200μl of the primary antibody. 
This antibody has to be diluted in an appropriate amount of 1xPBS ( see antibody 
table) 
 Incubate the cells for approximately one hour at room temperature or over night at 
4°C. 
 Wash the cells three times with 1ml 1xPBS 
 Add 200μl of the second antibody which is diluted in 1xPBS and additionally  DAPI 
which is added in a ratio 1:1000 to make the cell´s nulclei visible 
 After 30 minutes wash the cells three times with 1ml 1xPBS 
 Wash one time with 1ml destilated H₂O 
 Cells in a 2 well glass slide are fixed with a specific glass and on cells in a 24 well 1ml 
is transferred on the cells to avoid drying out 
 The cells can be stored at -20°C 
      2.7.2 FACS  (Fluorescence activated cell sorting) 
 Cells are grown in a 10 cm dish 
 Wash the cells with 10 ml 1xPBS 
 Add 500µl Trypsin 
 Stop the trypsinization with 1ml of a certain media and 9 ml 1xPBS 
 Transfer the cells in 15 ml Falcon tubes 
 Collect the cells by centrifugation at 1300rpm for 4 minutes and aspirate supernatant 
 Add 1ml 4% Formaldehyde 
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 Fix the cells for 10 minutes at room temperature 
 Chill the tubes on ice for 1 minute 
 Centrifuge the cells at 1300 rpm for 4 minutes and resuspend the pellet in 1ml     90% 
methanol 
 Incubate the cells for 30 minutes on ice 
 Cells can be stored at -20°C or they can be stained 
 For the staining, 3ml Incubation Buffer (10% BSA in 1x PBS) is added to the cells in 
the Falcon tubes to remove the methanol 
 Centrifuge the cells at 1300 rpm for 4 minutes 
 The cells are divided in the amount of samples that should be analyzed in the end by 
flow cytometry. Resuspend the pellet in a certain amount of Incubation Buffer so that 
each sample consists of 2 ml buffer ( e.g. 5 samples->  cells are resuspended in 10 ml 
Incubation buffer) 
 Centrifuge the cells at 1300 rpm for 4 minutes 
 Remove the Incubation buffer and add 80µl of fresh Incubation buffer 
 Transfer the cells from the Falcon tube in 1,5ml Eppendorf tubes 
 Resuspend the cells per assay tube for 10 minutes 
 Add 1µl of the determinate primary antibody to each samples and if needed make an 
additionally  Flag antibody sample as control 
 Incubate the primary antibody for 1 hour at room temperature 
 Add 1ml Incubation buffer and transfer the cells from the Eppendorf tube  to a 15ml 
Falcon tube 
 Pellet the cells at 1300 rpm for 4 minutes by centrifugation 
 Discard the supernatant and resuspend the pellet in 3ml Incubation buffer 
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 Centrifugate the cells at 1300 rpm for 4 minutes 
 Remove the supernatant and add 80µl Incubation buffer and transfer the cells to a 
1,5ml Eppendorf tubes. Altogether, 100µl of cells solved in Incubation buffer should 
be in the eppi tube. Now add 0,5µl of the specific second antibody to the samples 
 Incubate for 30 minutes 
 Add 1ml Incubation buffer and transfer the cells from the eppi to a 15ml Falcon tube 
 Centrifugate the cells at 1300 rpm for 4 minutes 
 Resuspend the pellet in 300µl PBS and transfer the cells into specific FACs tubes and 
analyze the staining on the flow cytometer.  
2.7.3 Propidiumiodide staining 
 Remove the old media 
 Wash the cells with 1x PBS 
 Trypsinize the cells 
 When the cells detach from the plate add 1ml of the appropriate media and 9ml of 
1xPBS 
 Centrifuge the cells at 1200 rpm for 4 minutes 
 Resuspend the pellet in 200µl 1xPBS 
 These 200µl dissolved cells are added drop by drop to 800µl 85% Ethanol. It is 
important during this procedure the mixture is vortexed 
 The cells can be stored at -20°C or they are centrifuges at 1400 rpm for 4 minutes 
 The pelleted cells are resuspended in 250 µl propidiumiodide buffer 
 After 30 minutes of incubation centrifuge the cells at 1400 rpm for 4 minutes 
 Dissolve the cells in 300 µl 1xPBs and analyze the  distribution of the cells in the cell 
cycle via flow cytometry 
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 Propidiumiodide buffer ( Stock: 50µg/ml):  
                                117 mg trisodiumcitrat peroxide 
                                25mg RNASE 
                                5mg propidiumiodide 
                                0,1ml Triton X100 
                                                                   Fill up to 100ml with dH₂0 
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2.7.4. Western Blot 
2.7.4.1. Chemicals 
 Acrylamide solution: 30% Acrylamide 
                                  0,8% N,N´-Methylenbisacrylamide 
 
 Buffer B (ph 8,8): 1,5M Tris              36,3 g Tris , adjust ph 
                                          0,4% SDS             4ml 20% SDS, fill up to 200 ml 
 
 Buffer C(ph 6,8): 0,5M Tris               12,16 Tris, adjust ph 
                                         0, 4% SDS              4ml 20% SDS, fill up to 200 ml 
 
 4x Loading Buffer: 50 µl 2M Tris ph 6,8                    200mM 
                                200µl 1M DDT                            400mM 
                                0,04g SDS                                    8% 
                                0,002g Bromphenolblau               0,4% 
                                200µl Glycerol                              40%  
 
 10x Elekrtophoresisbuffer: 60,6g Tris 
                                            292g Glycine 
                                            100 ml 20% SDS, fill up to 2l 
 
 Harlow Buffer ( Transferbuffer): Tris-Base                  29g 
                                                     Glycine                     145g 
                                                     20%SDS                   25ml 
                                                     dH₂O                         4l 
                                                     Methanol                   1l 
                                                                                                      Store at 4°C 
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 10x Tris: 1,5M NaCl                                                     175,32g 
               0,5M Tris ph 7,4                                            121,14g 
 Fill up to 1800ml with dH₂O and adjust ph with 37% HCl and then fill up to 2l mark 
 
 1x TBS/T: 100ml 10x TBS 
                  1ml Triton-X-100 
                   Fill up to 1l with dH₂O 
 
 
2.7.4.2 Index for Gels 
Running gel 
 5% 7% 10% 10,5% 11% 12,5% 15% 
Total volume 12ml 12ml 12ml 12ml 12ml 12ml 12ml 
Solutions        
Acryl Amide 2ml 2,8ml 4ml 4,2ml 4,4ml 5ml 6ml 
Buffer B 3ml 3ml 3ml 3ml 3ml 3ml 3ml 
dH₂O 7ml 6,2ml 5ml 4,8ml 4,6ml 4ml 3ml 
10% APS 120µl 120µl 120µl 120µl 120µl 120µl 120µl 
TEMED 10µl 10µl 10µl 10µl 10µl 10µl 10µl 
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Stack gel 
 5% 
Total volume 3ml 
Solutions  
Acryl Amide 0, 5ml 
Buffer C 0,75ml 
dH₂0 1,75ml 
10% APS 30µl 
TEMED 2,5µl 
 
2.7.4.3 Bradford 
 Dilute the Bradford solution 1:5 with destilated water 
 Filtrate this Bradford mix  
 Add 1ml in a cuvette specific for the Bradford measurement. It has flat and ribbed 
surfaces. The orientation of the cuvette in the Biophotometer is important. The flat 
surface has to look in the direction of the researcher. 
 Add 1µl of the measured proteinextracts to the Bradford solution in the cuvette and 
wait 5 minutes 
 As blank, 1µl of the lysis buffer (usually NP40 buffer) is added to the Bradford 
solution 
 When measuring, first put the Blank in the Photometer and push the “Blank” button 
 Afterwards the proteincontent in each sample can be measured when pushing the 
“Sample” button 
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 At the end the blank is measured again but this time by pushing the “Sample” button. 
No proteins should be measured. 
2.7.4.4 Western Blotting 
 According to the size of the protein, the running gel is mixed in the certain percentage 
(see index for gels) 
 The running gel is filled between two glass slides and in the middle a comb creates the 
wells for the samples 
 On the top of the running gel destilated water is pippeted to straight the gel 
 After polymerization the water is discarded and the stack gel is transferred on the 
running gel and additionally the comb is placed on the top of the gel 
 After boiling the samples at 95°C, chill the tubes on ice and fill up the protein extracts 
with the certain amount of buffer A and 4x loading dye. The total volume depends on 
the amount of wells but generally up to 15µl can be placed within one line 
 
                                                            
Fig.14: SDS Page apparatus: www.2.chemistry.gatech.edu/.../page_protein.html 
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 Fill up the box , in which the gel between the two glass slides is placed, with             
1x electrophoresis buffer 
 The SDS-Page runs at 50 V until a straight line can be seen and afterwards the gel can 
be run at 110 V 
 When the loaded samples reach the end of the gel the next step is the blotting on the 
nitrocellulose membrane 
 Therefore a so called “sandwich” is generated. It consists of the following assembly: 
sponge,2x Whatman Paper, SDS-gel, nitrocellulose membrane, 2x Whatman Paper, 
sponge       
 
Fig.15: “Sandwich”  Formation: www.stanxterm.aecom.yu.edu/wiki/index.php?page=Western_blotting 
 
 The blotter runs for one hour at 350 mA 
 To ensure that proteins are present on the nitrocellulose membrane, it is stained for   
10 minutes with Ponceau-S 
 Afterwards the membrane is washed 3 times for 10 minutes with TBS/T 
 Following this 30 minutes the membrane is blocked for one hour against unspecific 
binding with a 5% milk -TBS/T blocking buffer 
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 Remove the blocking buffer and wash the membrane 3 times for 10 minutes with 
TBS/T 
 The next step is the incubation of the primary antibody. For this reason the antibody is 
usually diluted 1:1000 in a 5% BSA-TBS/T solution. If the primary antibody is a weak 
one, the incubation lasts over night at 4°C while gently shaking 
 The following day the primary antibody is removed and the membrane is washed 3 
times with TBS/T for 10 minutes. The primary antibody can be collected in a 15 ml 
Falcon and can be stored at 4°C for about one month 
 After the washing step the membrane is incubated with the second antibody that is 
usually diluted 1:10 000 in a 5% milk-TBS/T buffer 
 One hour later wash the membrane again 3 times with TBS/T f or 10 minutes 
 Discard all the wash solution and incubate the membrane with the ECL solution for 
one minute 
 Rinse off the ECL solution and enwrap the membrane in a saran wrap 
 But the membrane onto a film cassette 
 Put in either a blue film or a grey one that is more sensitive and expose the assessed 
time 
 Develop the film 
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2.7.4.5.Stripping the nitrocellulose membrane  
 Stripping buffer: 1M Tris (ph 6,7)              9ml 
                10% SDS                         30ml 
                Β-Mercapthoethanol       1ml 
                dH₂O                               110ml 
 Mix the stripping buffer and incubate the membrane in a 55°C water bath for  
10 minutes 
 Wash the membrane two times with TBS/T for 3 minutes 
 Incubate the membrane for one hour with a 5% milk-TBS/T buffer 
 Wash the membrane 3 times with TBS/T for 10 minutes 
 Following to this, the membrane gets incubated with the primary antibody 
 Next steps identical with normal western blotting ( see above) 
2.7.5 Glucosaminoglycan assay (Blyscan sGAG assay; Biocolor)  
 Remove the old media of the chondrocyte pellets, collect each pellets in 10 µl 1xPBS 
and transfer them into 1,5ml Eppendorf tubes. In total there should be at least 50µl 
1xPBS in each tube 
 Add 1µl Proteinase K stock solution to the 50µl 1x PBS 
 Incubate over night at 37°C 
 Use 10µl digested solution for DNA measurement and 15-20µl for GAG measurement 
 For DNA quantification mix 10µl of the digested solution with 100 µl DAPI 
(0,5µg/ml) and transfer the mixture in a 96 flat bottom well 
 Incubate the DNA-DAPI blend for 10 minutes at room temperature, shake it from time 
to time 
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 Read fluorescence at 360 nm excitation and 460 nm emission 
 For GAG measurement mix around 20 µl of the digested solution with 250µl of 
Blyscan dye reagent in a 1,5 ml Eppendorf tube 
 Also include positive controls: blend 2µl, 4µl, 8µl, 16µl, 32µl in each eppi filled with 
250µl of Blyscan dye reagent 
 Shake the tubes for 30 minutes at room temperature by a thermoblock 
 Centrifuge the samples full speed for 10 minutes at 4°C 
 Remove the supernatant and dry the tube. A violet pellet can be seen 
 Add 150µl Dissociation dye to each tube 
 Vortex the tubes for 10 minutes 
 Transfer the dissolved pellet into a 96 flat bottom well 
 Empty control:150µl Dissociation reagent 
 Positive controls: 2µl, 4µl, 8µl, 16µl, 32µl in each eppi filled with 250µl of Blyscan 
dye reagent 
 Read at 630 nm absorbance 
 
2.8 Growth rate measurement 
 Suck off the old media 
 Wash the cells with 1xPBS 
 Trypsinize the cells 
 Add 3ml media and stop the trypsin 
 Collect the cells in a 15ml Faclon tube 
 From these 3ml take 10µl and transfer them into 5ml Casy ton 
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 Measure how many cells are in 1ml media and note the amount in a list 
 Plate around 300 000 cells ( depending on the result from the Casy measurement) in a 
new 6 well plate 
 Repeat this procedure every second day and always plate the same amount of cells in a 
new 6 well plate ( in this case 300 000) 
 With the collected data a growth rate curve can be generated 
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3.Results 
 
3.1 Growing potential of patient derived hAFSC 
 
 
Fig.16: Growth rate of patient derived hAFS 
Human amniotic fluid stem cells were derived from pregnant women. They grow in chang 
media without evidence of spontaneous differentiation and without sudden termination of 
growth. Within the samples, different cell types with different morphologic appearance can be 
discovered. Long, round, flat, small and crescent-shaped cells compose the cellular part of the 
amniotic fluid. At day 10 the cells are 80% confluent and can be amplified by passaging. 
To further investigate if these cells harbor the potential of stem cells, the marker expression 
was assayed via Immunofluorescence staining (see Materials and Methods                           
2.7.1 Immunofluorescence). 
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3.2 Marker expression of patient derived pool of hAFSs 
 
Fig.17: Marker expression of hAFSC 
To determine marker expression of the cells within the human amniotic fluid, cells were 
stained with cytokeratin 18.CK18 is usually a marker for epithelial cells and Vimentin is a 
cytoskeletal protein present in mesenchymal cells including fibroblasts, chondrocytes and 
endothelial cells.The expression of the two stem cell markers Oct-4 and the embryonic 
antigen-4 (SSEA4) presented the stem cell specific capacity of amniotic fluid cells. As 
control, the cells were stained only with the second antibodies whereas the cell´s nuclei were 
made visible by DAPI staining. 
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3.3 Single cell dilution of CD117/2 cells   
 
 
Fig.18: Generation of CD117/2 single cell clones 
Single cell clones were generated via single cell dilution (see Materials and Methods:          
2.5 Single cell dilution). The starting cell line was the magnetic beat sorted CD117/2. Based 
on these cells, CD117 single cell clones arose and were named SCC (single cell clone) A-Q. 
These clones could be grouped according to their size, their marker expression, cell cycle 
distribution and growth rate. One group was composed of the SCC I, C, and U the other of 
D,K and O ( O not shown). The first group is characterized by spindle-shaped cells which 
grow very fast, similar to the based cell line CD117. The cells of the latter group have a more 
flat morphology and the growth rate is very low compared to the other group (more detailed 
growth rate investigation see Materials and Methods: 2.8 Growth rate measurement) 
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3.4 Distribution in the cell cycle 
 
 
Fig.19: Distribution of CD117/2 and CD117/2 single cell clones in the cell cycle 
The cell cycle distribution Aneuploidy  can be investigated by staining the cells via 
propidiumiodide staining (see Materials and Methods: 2.7.3 Propidiumiodide measurement). 
Two peaks can be seen which demonstrate the two phases of the cell cycle: the first peak 
represents G1 and the second one G2. In between is the S phase (synthesis phase). Most of the 
cells arein the G1 phase. The fact that no additional peak is present demonstrates that the cells 
have a normal karyotype with no additional chromosomes. Additionally it can be seen that the 
CD117/2 single cell clones K, I ,C and U have a similar distribution and peak appearance as 
the basic CD117/2 cell line from which they originate. The cell sizes can also me 
demonstrated in the flow cytometry. The forward scatter (FSC-H) indicates the size of the 
various single cell clones (see Fig.20). Two groups can be differ: the SCC C with a smaller 
cell size (C,I and U) and those whose cell size is bigger ( A,D and K). 
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Fig.20: Cell size of single cell clones via flow cytometry. 
3.5 Growth rate of CD117/2 single cell clones 
The speed of growth of the various single cells together with the origin CD117/2 cell line was 
measured every two days in a cumulative cell proliferation assay (see Materials and Methods: 
2.8 Growth rate measurement). As in the Fig.21 shown, the primary CD117/2 cell line grew 
faster than the other single cell clones. SCC C,I and U have a similar growth rate whereas A 
and O form the other group. Additionally the human amniotic fluid stem cell line Q1 was used 
as a control. All cell lines share a logarithmic growth. 
                        
Fig.21: Growth rate of various cell lines 
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3.6. Marker expression of single cell clones 
The single cell clones were stained for the pluripotent stem cell factor Oct4. To test whether a 
mouse or a rabbit Oct 4 primary antibody achieves a stronger signal two different Oct4 
antibodies were used. Additionally, the cells were stained with Nestin. On the one hand it is a 
stem cell marker but on the other hand it also serves as indicator for neural progenitor cells.  
  
Fig.22: Marker expression of single cell clones; note : The in the graphic demonstrated SCC Q is the SCC U 
When focused on the expression of the two Oct4 markers again the SCC C, I and U (in the 
graph SCC Q) have the highest level of expression among the CD117/2 single cell clones 
which allows again a classification in the groups noted above. Interestingly, these three single 
cells have the smallest nuclei size within the observed cell lines. Additionally, the staining of 
the primary mouse Oct4 antibody (sc 5279) exhibits a stronger signal compared to the rabbit 
one (sc-9081). These immunofluorescence experiments confirm that single cell clones express 
Oct4 and that the single cell dilution is a successful tool to isolate cells with different 
expression patterns. 
1-4 are arbitrary Units  
according to a scale: 
 = % positive cells 
4 = > 20% 
3 = 10% 
2 =5% 
1=2, 5% 
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3.7 Chondrogenic pellet formation 
 
   
   
   
   
  
Fig.23: Pellet formation by CD117 SCC 
 
 
 
No pellet formation happens 
The edge lifts on one edge of the 
pellet. A functional pellet cannot be 
generated 
A round pellet is visible hours but it 
has not the same density within the 
pellet 
The pellet is almost perfect but if 
closer examined small appendages 
arise on the edge of the pellet 
A perfect round pellet is formed . 
The edges are straight and a 
compact surface can be seen 
Hours 
0 
12 
24 
48 
72 
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To further investigate the effects of pharmacological substances on pellet formation, the 
pellets were incubated with the two mTOR inhibitors, Rapamycin and Torin, the transforming 
growth factor TGFβ and combinations of these compounds. To define the effects of the 
chemicals in a scoring system, the five proto-types of formed pellets (see Fig.24) were used. 
    
   
 
Fig.24: Ability of pellet formation depending on chemical addition. Rapamycin = 20nM, Torin=250nM. 
The three single cell clones CD117/2 I, C and U are tested for their ability to form pellets. 
After the procedure of the pellet formation (see Materials and Methods 2.6: Pellet formation 
for chondrogenic differentiation) the addition of various chemical substances affected the 
formation in either a positive or a negative way. The growth factor TGFβ enhanced the 
formation in all three cells lines compared to untreated pellets (+DMSO). The mTORC1 
inhibitor Rapamycin only led to a light decrease in the ability to form pellets but a modest 
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decrease can be seen in SCC C. On the other hand, incubation with the total mTOR 
(mTORC1 and mTORC2) inhibitor Torin induced a very strong decrease mostly affecting 
SCC I and C. Combinations of TGFβ and Rapamycin induced an increase in the ability to 
form pellets (in SSC I and U) whereas incubation of TGFβ and Torin featured the negative 
effects of Torin and no round pellets could be formed. All these observations were made 
within 24 hours. After 48 hours the CD117 single cell clones I, C and U could form almost 
perfect pellets even when incubated with most of the chemical substances mentioned above. 
However, pellets could not be formed by the cells when treated with the total mTOR inhibitor 
Torin. 
3.8 Kryocut and staining of chondrocyte pellet 
Chondrogenic pellet of SCC I is cut after 14 days. Via the Gimsa staining cell nuclei can be 
made visible. Dimethylmethylenblue (DMMB) stains the sulfated glycosaminoglycane within 
the pellet. Immunofluorescence studies reveal that at the edge of the pellet a strong Sox9 
expression can be observed whereas towards the middle more differentiated cells which 
express markers like Vimentin are located. 
 
Fig.25: Kryocut and staining of a chondrogenic pellet 
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3.9 GAG assay of CD117 SCC I,C and U 
          
   
      
Fig.26: GAG amount of CD117 SCC; Rapamycin = 20nM, Torin=250nM. 
After the pellets were lysed (see Materials and Methods: 2.7.5 Glucosaminoglycan assay) the 
amount of the Glycosaminoglycans were measured by using the GAG assay kit. In chang 
media all three single cell clones already had a basal amount of GAGs but the production can 
be increased by treatment with TGFβ. A very strong induction of GAG synthesis can be seen 
in SCC U (see Fig.26). When treated with the mTORC1 inhibitor Rapaymcin an enhancement 
of GAGs also can be observed. The level is similar but little bit smaller to the TGFβ effect. 
Compared to the TGFβ and Rapamycin levels of GAG production, Torin leads to a decrease 
in generation of these extracellular matrix compounds. Combinations of TGFβ and 
Rapamycin lead to an equal level as TGFβ and Rapamycin alone but combination with Torin 
induced suppression of the stimulating effects of TGFβ. Interestingly, Torin affects only 
CD117 SCC I and C and no inhibitory effects can be observed in SCC U. 
 
 
 
CD117 SCC I CD117 SCC C CD117 SCC U 
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3.10 Western blot analysis  
3.10.1 Testing of pharmacological substances 
We tested various pharmacological substances for their potential to block certain components 
of the mTOR signaling pathway. At first pellets were treated with the two pharmacological 
inhibitors (Rapamycin and Torin) for 30 minutes. Afterwards TGFβ was added for another 
half an hour to certain pellets. The pharmacological substances were added in the following 
concentrations: Rapamycin: 20nM, Torin 250nM, MK2206 1μM. TGFβ induced a modest 
phosphorylation signal of Akt and together with the mTORC1 inhibitor Rapamycin this signal 
could not be diminished. In addition Rapamycin alone did not inhibit the formation of pAkt at 
S473. A total inhibition of the pAkt signal could be observed when pellets were treated with 
the mTOR inhibitor Torin or the Akt specific inhibitor MK2206. Focusing on the mTORC1 
substrates p70S6k and pS6 their activations were avoided when Rapamycin and Torin were 
added. As expected, a signal could be observed in the presence of MK2206. A similar 
inhibition pattern can be observed in SCC I and C but contrary to SCC I Rapamycin does not 
block the phosphorylation signal of S6 that strong in SCC C. 
 
              Fig.27: Testing of pharmacological inhibitors; Rapamycin = 20nM, Torin=250nM, MK2206=1μM 
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3.10.2 mTOR activity after 48 hours in the chondrogenic pellets 
                                            
       
 
 
 
 
 
Fig.28: Western blot analysis after 48 hours, Rapamycin = 20nM, Torin=250nM, MK2206=1μM 
After 48 hours incubated in chondrogenic media, phosphorylation of the mTOR substrate Akt 
is present in the CD117 SCC I and C (Fig.28). The phosphorylation on S473 leads to a full 
activation of Akt which is upstream of the mTORC2. The phosphorylation level is influenced 
by various substances. TGFβ enhances phosphorylation of Akt whereas Rapamycin and Torin 
reduce the activation in SCC I but not SCC C compared to the control (no treatment with 
chemical substances). The strongest phosphorylation can be seen when TGFβ together with 
Rapamycin is added to the chondrocyte differentiation media.  In SCC C the phophorylation 
levels of Akt are all similar except treatment with Torin alone. A light decrease can be 
observed. Interestingly, Rapamycin induces phosphorylation to the highest Akt 
phosphorylation level observed within this cell line. The 70S6 kinase gets phosphorylated at 
T389 when the mTOR pathway is activated. The phosphorylation of this downstream kinase 
indicates that the mTOR pathway is activated in the chondrogenic pellets. In CD117 SCC I 
70S6kinase phosphorylation is only present when TGFβ is added to the media even ithough 
the signal is very weak. Addition of Rapamycin, Torin or the combination of those two 
inhibitors with TGFβ prevents phosphorylation. Controversally, in SCC C 70S6kinase 
phosphorylation can be observed best when no chemicals are added. Furthermore, a slight 
tgfb  -  +  -  -  +  +  
 rapa  -  -  +  -  +  -  
torin  -  -  -  +  -  +  
tgfb  -  +  -  -  +  +  
rapa  -  -  +  -  +  -  
torin  -  -  -  +  -  +  
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band can be seen on the film when TGFβ is used. As loading control, the membrane was 
incubated with GAPDH. It is a housekeeping gene and serves to ensure that in all samples the 
same amount of protein is present.  
3.10.3  mTor and chondrogenic marker expression after 7 days in chondrogenic pellets   
 
                     
 
Fig.29: Marker espression profile after 7 days, Rapamycin = 20nM, Torin=250nM, MK2206=1μM 
After 7 days of culturing the pellets, a modified expression pattern occurs. This time only the 
CD117 single cell clone C was investigated (Fig.29). The phospohorylation signal of Akt is 
very strong when TGFβ was present compared to the chondrogenic differentiation media 
alone. Because of the negative feedback loop, blocking of mTORC1 by Rapamycin 
compensates the inhibitory effect of p70S6K on IRS1 and according to this, IRS1 induces the 
activation of mTORC2 and its substrate Akt when pellets were treated with Rapamycin. Torin 
totally blocks the phosphorylation even when the inducer TGFβ is used. As expected, the 
addition of TGFβ and Rapamycin generate the activation of Akt on a high level. Furthermore, 
the phosphorylation status of 70S6kinase is similar to the expression pattern on day 2. 
GAPDH is used as loading control. To examine if the human amniotic fluid stem cells show  
chondrogenic characteristics the samples were stained for the expression of the two main 
markers of chondrocytes , Collagen 2AI and Sox 9. A light band can be seen when the 
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membrane was incubated with the Collagen 2AI antibody indicating a successful 
differentiation of the stem cells into chondrocytes. As anticipated, the bands occur only when 
the samples were treated with the chondrogenic differentiation media and with TGFβ only.                                                          
Fig.29 confirms that human amniotic fluid stem cells can differentiate into chondrocytes and 
shows the marker expression of Sox9. It is a characteristic marker of chondrocytes and after 7 
days a strong induction of the marker expression can be observed. Only Torin has the 
potential to block the Sox9 signal after 7 days, Rapamycin and MK2206 do not reveal a 
change of the expression level compared to the TGFβ treatment (in Fig.29 MK2206 not 
shown). GAPDH shows that too little protein is loaded when pellets were treated with TGFβ 
together with Torin. 
3.10.4 Time dependent expression of Sox9      
 
Fig.30:.Induction of the Sox 9 expression during 7 days, Rapamycin = 20nM, Torin=250nM, MK2206=1μM 
An induction of the chondrogenic marker Sox9 can be observed after day 2 and the expression 
increases in a time dependent manner. The longer the pellets are incubated din the 
chondrogenic differentiation media the more Sox9 expression appears. Additionally the 
expression can be enhanced by adding TGFβ to the media (see right Blot). After one day a 
slight band can be seen whereas on day 7 Sox9 is expressed on high levels. TGFβ stimulates 
this expression. During differentiation, cells within the pellet loose other differentiation 
markers such as Cytokeratin 7. This reveals a successful differentiation from stem cells into 
chondrocytes. 
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4.Discussion 
The main focus of our studies was to investigate the differentiation potential of human 
amniotic fluid stem cells into chondrocytes. Therefore the expression pattern of the cells 
before and after the pellet culture was analyzed. We expected that before the differentiation 
hAFSC express stem cell markers like Oct4, SSEA4 and CD44 but when cultured in 
chondrogenic differentiation media these markers disappear and markers characteristic for 
chondrocytes such as Sox9, Col2A1 and sulfated Glycosaminoglycans are expressed.  
 
 
Fig.31: Working model 
 
After single cell clones were generated out off the magnetic beat sorted,  human amniotic 
fluid stem cell line CD117/1, pellets were formed and treated with various pharmacological 
substances. We hypothesized that the addition of the transforming growth factor β (TGFβ) 
enhances the expression of the chondrogenic markers and therefore the differentiation of 
hAFSC into chondrocytes, whereas the mTOR inhibitor Torin blocks their expression. 
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Fig.32: Working model of the impact of chemical substances on the chondrogenic marker expression 
Starting from an amniotic fluid sample derived by amniocentesis, Immunofluorescence 
staining reveals that amniotic fluid is composed of cells from different origins. Staining with 
Cytokeratin 18 antibody demonstrates epithelial derivation and a moderate signal of SSEA4 
and Oct4 shows that also cells with stem cell capacity can be found within the amniotic fluid. 
To exclude that the differentiation of hAFSC into chondrocytes is due to already 
differentiated cells in the pool of hAFSC, monoclonal single cell clones derived from the 
magnetic bead sorted cell line CD117/1 were generated. In total 17 single clones could be 
generated with different sizes and growth rates. Because some of the clones stopped growing, 
only six SCC were used for further experiments. These six cell lines were divided into a group 
of fast growing cells with small nuclei (C,I,U) and a group with the opposite appearance         
( A,K,O). Additional Immunofluoresecnece staining confirmed this classification. In the next 
step pellets were generated out of the fast growing SCC C,I , U and they were incubated in the 
chondrogenic differentiation media including combinations of TGFβ, the mTORC1 inhibitor 
Rapamycin and the total mTOR inhibitor Torin. Interestingly, the ability to form pellets was 
affected by the addition of  these chemical substances. After one day TGFβ stimulated the 
formation of total round pellets in the SCC I and C whereas Rapamycin had a moderate 
inhibitory effect and Torin strongly diminished the pellet formation of these two clones. 
Combinations of TGFβ and Rapamycin had a positive effect but in combination with Torin 
TGFβ could not accomplish its stimulating outcome. These phenomena could not be seen in 
pellets of SCC U cells. After 48 hours of pellet formation all pellets were perfectly round 
except when Torin was added to the chondrogenic differentiation media. The same impacts of 
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TGFβ, Rapamycin and Torin could be observed when the SCC were analyzed for their 
sulfated glycosmaninoglycans. Because moderate effects could be seen in SCC I and C these 
two cell lines were also used for Western Blotting. We focused on the expression of various 
mTOR compounds and on the chondrogenic markers Sox 9 and Collagen 2A1. After 48 hours 
a strong induction of the phosphorylation of the mTORC1 downstream substrate Akt could be 
observed when TGFβ was added to the CD117 I and C pellet cultures. An inhibition of the 
phosphorylation could be seen when Rapamycin and Torin was present in the media of the 
SCC I whereas a reducing effect of Rapamycin in SCC C could not be observed. When 
stained for the phosphorylation of the kinase p70S6K a light band could be seen on the blot 
for SCCI but only when the pellets were incubated with the differentiation media alone or 
plus TGFβ compared to SCC C in which the strongest band could be seen in pellets which 
where treated in the pure chondrogenic media. Additionally a faint band could be seen in 
pellets with TGFβ whereas Rapamycin, Torin and the combinations of these inhibitors with 
TGFβ abrogated the phosphorylation of 70S6K. 
After 7 days the effects of the chemical substances in the SCC C were even stronger than after 
48 hours. The phosphorylation signal of Akt  was fully diminished when Torin was added but 
TGFβ as well as Rapamycin were supplemented to the differentiation media the Akt 
phosphorylation was enhanced compared to the pellets incubated in the media alone. After 7 
days the expression of p70S6K was again on the highest level in pellets treated without any 
additional substances except the chondrogenic media. A slight induction could be seen when 
the pellets were incubated with TGFβ. Additionally to these results an induction of 
Collagen2A1 and Sox 9 can be observed after one week. This signal could be enhanced by the 
addition of TGFβ. 
Because bones and cartilage are avascular tissues, hence without oxygen supply, we used the 
so called pellet formation method. The cells are packed in a compact form and grow in 0% 
serum which is similar to the environment in vivo in which nutrients and oxygen are only 
available in low amounts.  
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Fig.33: Kryo cut of a pellet 
In the cut pellet the dense cells can be seen via their stained nuclei. This tightly arrangement 
especially on the edge of the pellet ensures that the cells are in a low oxygen state so that the 
properties of the cells which form the pellet are comparable to the chondrocytes in the bones 
and avascular cartilage of the human body. The state of low oxygen (hypoxia) has an impact 
of the expression of the chondogenic markers Sox9, Collagen 2A1 and Collagen 9A1. The 
enhancement of marker expression is due to the hypoxia-inducible factors HIF -1α and     
HIF-2α and if the latter is knocked down by HIF-2α specific siRNA these stimulation marker 
is diminished [27]. If the pellets are exposed to 20 % oxygen (normoxia) the increased levels 
of the characteristic chondrogenic markers also cannot be observed [27]. Because of this 
findings we decided to let the cells grow in pellets and for that matter we got a significant 
induction of the expression of Sox9 and a satisfing result concerning the Collagen2A1 
expression.  
Chondrogenic media components 
Insulin-transferin-seline (ITS): The chondrogenic differentiation media consists of 
compounds which promote the differentiation of the hAFSC into chondrocytes. As mentioned 
in 1.3.2 marker expression of chondrocytes, insulin is a potent regulator of cell proliferation 
and differentiation by binding to its specific receptors on the cell membrane and so the mTOR 
pathway is activated. For this reason one compound of the differentiation media is ITS which 
is composed of insulin.  
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Ascorbic acid: Another key regulator of chondrogenic differentiation is ascorbic acid. It can 
activate the expression of the characteristic genes of chondrocytes such as Sox9, Collagen II, 
Collagen X, Indian Hedgehog and Runx2. Temu et al. demonstrated that ascorbic acid alone 
without any addition of growth factors can induce chondrogenic differentiation. Cells that 
grow in α-MEM media do not express chondrogenic makers whereas in cell treated with 
ascorbic acid within the α-MEM media show a strong expression pattern of these markers 
[37]. The same effect can be observed when cells were treated with DMEM-F12 media with 
or without ascorbic acid. In this study it was hypothesized that ascorbic acid promotes cell 
proliferation and differentiation into chondrocytes by supporting the generation of collagen 
triple helices and according to this the synthesis of the collagenous extracellular matrix. 
Ascorbic acid is required for the hydroxylation of procollagen and for its processing and 
additionally it induces collagen fibril assembly and collagen secretion [38-40]. For all these 
processes the activation of the ERK pathway is required. If this pathway is blocked, ascorbic 
acid has a limited capacity to promote chondrogenic differentiation. The ERK pathway gets 
activated when ascorbic acid is present. This can be proven by Western immunoblotting. Cells 
cultured in α-MEM media containing ascorbic acid have a high expression level of 
phosphorylated and therefore activated ERK compared to cells treated with α-MEM media 
alone. The fact that ascorbic acid alone can already promote differentiation of chondrocytes 
and that it is independent of the IGF-1 and insulin pathway was also demonstrated by Temu et 
al. Treatment of cells with IGF-1 or insulin lead to a decrease in their specific receptors 
because of ligand-induced receptor endocytosis and degradation. In contrast, during ascorbic 
acid stimulated differentiation the amount of IGF-1 and insulin receptors does not change 
what leads to the conclusion that ascorbic acid works in an independent manner without the 
need of induction of IGF-1 or insulin. Additionally it is a ROS scavenger and therefore 
prevents damage of cartilage by oxygen stress. 
Dexamethasone: The glucocorticoid Dexamethasone promotes chondrocyte differentiation by 
regulating the Sox9 expression. Sekiya et al. [41] demonstrated that within 48 hours 
Dexamethasone can enhance the expression of Sox9 compared to control cells which were not 
treated with this glucocorticoid. This stimulating effect is dose dependent and reaches its 
maximal effect at 10 nM. Furthermore, Dexamethasone is specific for the upregulation of 
Sox9 because the expression level of Sox 6, an other members of the Sox family, was 
unaffected when treated with Dexamethasone. Induction of Sox9 expression leads to an 
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enhancement of the Col2A1 expression level because as a transcription factor, Sox 9 can bind 
to the promoter region of Col2A1 what induces the expression of this marker. 
 TGF β: A very potent regulator for the induction of extracellular matrix synthesis is the 
transforming growth factor β (TGFβ) which signal via Smad molecules, but also activates 
MAPK,PI3K and the mTOR pathway. Subsequently it also drives activation of the tissue 
inhibitor of metalloproteinases-3 (TIMP-3), which mediates the blocking of matrix 
metalloproteinases and aggrecanases which degrade the extracellular matrix and Collagen II. 
TGFβ activates the mTOR pathway by inducing the phosphorylation of Akt. This activation 
process can be inhibited by the PI3K inhibitors Wortmannin and LY294002 as well as by the 
Akt inhibitor NL-71-101. Furthermore the mTOR inhibitor Rapamycin can inhibit the TGFβ 
stimulated phosphorylation of the mTORC1 downstream substrate 70S6K and the impact of 
TIMP-3 [42]. The TGFβ family is important for the repairing mechanisms in rheumatoid 
arthritis, osteoarthritis and aged cartilage. This growth factor is generated in monocytes-
macrophages, platelets and chondrocytes and it is required for the survival of chondrocytes 
and extracellular matrix formation [43].  
 
Fig. 34: Effects of TGFβ on mTOR and on chondrogenesis 
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TGFβ signaling is elicited when TGFβ 1-3 bind to one of the two TGFβ receptors. The 
association of TGFβ with the type II receptor leads to a recruitment and phosphorylation of 
the type I receptor. This serine/threonine kinase gets activated and phosphoryltes the 
mediators of the TGFβ pathway, the Smad proteins. When Smad 2 is phosphorylated it 
interacts with Smad4. This oligomer translocates into the nucleus and binds to the DNA. This 
interaction of Smad2/4 and the DNA induces transcription of various genes of interest which 
express factors for chondrogenesis, cartilage repair and extracellular matrix synthesis. 
 
 
 Fig.35:TGFβ pathway :www.sigmaaldrich.com/life-science/cell-biology/learning-center/pathway-slides-
and/signaling-pathway-of-tgf-223.html 
Although SCC I and SCC C have a similar morphological appearance and their growth rates 
are comparable, Western blot analyzes, sGAG measurements and their ability to form pellets 
reveal a difference within these two cell lines. Whereas TGFβ has a stimulating effect on SCC 
I, SCC C does not respond to this growth factor. The strongest induction of marker expression 
appears when the cells are treated only with the chondrogenic differentiation media alone. 
According to this SCC C already express TGFβ in high levels from the beginning and no 
additional TGFβ is need to stimulate the expression of various markers. In contrast, 
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expression levels of the investigated markers in SCC I are just enhanced when TGFβ is added 
to the differentiation media. This difference in the TGFβ production can also be observed 
when measuring the sulfated glycosaminoglycans amounts in the two cell lines and 
additionally when the pellet formation ability is observed. 
Independently of this difference, the expression of various markers can be blocked by certain 
inhibitors in both cell lines. The mTORC1 inhibitor Rapamycin hardly effects the expression 
of the mTOR downstream component Akt whereas the total mTOR inhibitor Torin blocks Akt 
and p70S6K completely. In addition, the two chondrogenic markers Sox9 and Collagen 2A1 
are only expressed when Akt is activated. This pattern can be observed in Western blot 
analyzes as well as in the pellet forming ability and in sGAG measurements. 
We hypothesized that the differentiation form hAFSC into chondrocytes is regulated via the 
mTORC2 complex of the mTOR pathway because inhibition of total mTOR by Torin as well 
as blocking of Akt , the only substrate of mTORC2, by its specific inhibitor MK2206 reveal 
effects regarding the Sox9 expression, sulfated Glucosoamninoglycan generation and the 
ability to form pellets (the latter two properties were not investigated when pellets were 
treated with MK2206). Furthermore we designed a model in which the roles of the two 
mTOR complex in chondrogenic differentiation were defined. Chondrocyte which generate 
long bones are regulated via the mTORC1. Their development ends up in the hypertrophic 
sate, cells undergo apoptosis and minerlize. At the end the cartilaginous matrix gets replaced 
by bones. On the other hand, the mTORC2 is activated in chondrocytes who build up 
avascular cartilage. These cells survive and form the extracellular matrix. Those two 
chondrogenic types are characterized by their expression of various markers (see Fig.36). 
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Fig.36: Roles of the mTOR complexes in the two different types of chondrocytes 
Taken together we generated a protocol to differentiate hAFSC into chondrocytes via pellet 
formation. Chondrogenic marker expression confirmed a successful conversion into the 
desired cell line. Monoclonal stem cells assured that ckit positive cells within the amniotic 
fluid harbor the potential to differentiate into chondrocytes. For further perspectives, 
especially for degenerative joint and cartilage diseases like osteoarthritis or osteoporosis, it is 
important to establish protocols to generated a large amount of these cells which can be either 
directly  implanted into the damaged cartilage in vivo or to generate artificial articular 
cartilage in vitro. Another aim is to enhance the levels of Sox9 expression within damaged 
cartilage to regenerate damaged chondrocytes so that they can carry out their actual function. 
The origin for the differentiated chondrocytes, the amniotic fluid, is easily available during 
amniocentesis and can be expanded in large numbers. Because of their properties human 
amniotic fluid stem cells are a perfect source for the generation of chondrocytes and therefore 
also for the novel generation of articular cartilage. Degenerative diseases, from which more 
than half of people over 50 years old suffer, could be cured and quality of life could be given 
back to those patients. 
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5. Tabel of used materials 
 
Product name Company Cat.number 
30% acryl amide BioRad,Hercules,CA,USA 1610158 
6x Loading dye Promega,Fitchburg,WI,USA G1881 
α-MEM minimal essential 
medium 
Gibco-
Invitrogen,Carlsbad,CA,USA 
41061 
APS BioRad,Hercules,CA,USA 1610700 
BSA USB,Cleveland,OH,USA 10857 
Casycup Innovatis-Roche, 
Bielefeld,Germany 
43003 
Casyton Innovatis-Roche, 
Bielefeld,Germany 
43001 
Chang B+C Irvine Scientific, Santa Ana, 
CA,USA 
T101-019 
DAPI Sigma-Aldrich, St.Louis, 
MO,USA 
32670 
Dexamethasone Sigma-Aldrich, St.Louis, 
MO,USA 
D8893 
DMEM   
DMSO Sigma-Aldrich, St.Louis, 
MO,USA 
D5879 
ECL solution Thermo scientific, Pierce 
ECL western blot 
solution,IL,USA 
32106 
Foetal bovine serum/FCS PAA,Linz,Austria A-15-101 
Freezing tubes Almeco,Denmark 01-2000P 
Glas slides Lab-Tek-Thermo Scientific, 
Waltham,MA,USA 
155383 
Insulin-transferrin-sodium 
selenite 
Sigma-Aldrich, St.Louis, 
MO,USA 
I3146 
L-ascoric acid 2-phosphate Sigma-Aldrich, St.Louis, 
MO,USA 
A8960 
L-glutamin PAA,Linz,Austria M11-004 
Methanol Sigma-Aldrich, St.Louis, 
MO,USA 
17.995.7 
Nitrocellulose membrane Whatman,Maidstone,UK 10401396 
Non-fat dry milk BioRad,Hercules,CA,USA 170-6404 
PBS PAA,Linz,Austria H15-002 
Penicilin Sigma-Aldrich, St.Louis, 
MO,USA 
P3032 
PMSF Sigma-Aldrich, St.Louis, 
MO,USA 
P7626 
Ponceau-S Sigma-Aldrich, St.Louis, 
MO,USA 
P3504 
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Rapamycin Calbiochem,La Jolla, CA, 
USA 
553211 
TEMED Sigma-Aldrich, St.Louis, 
MO,USA 
T9281 
Tissue culture plates Nunc,Roskilde,Denmark 150326 
Triton X-100 Sigma-Aldrich, St.Louis, 
MO,USA 
T8787 
Trypsin/EDTA Sigma-Aldrich, St.Louis, 
MO,USA 
15950-017 
 
5.1 List of used antibodies 
5.1.1 Primary antibodies for Western blotting 
Name of antibody Cat.Number Reactivity with Dilution 
pAkt S473 Cell signaling 
4060S 
rabbit 1:10 000 
pS6Protein S240/244 Cell signaling 
22155 
rabbit 1:5000 
Sox9 (H-90) Santa cruz-
20095 
rabbit 1:1000 
Coll2A1 DSBH mouse 1:5000 
P70S6K Santa cruz-
9234 
rabbit 1:10 000 
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5.1.2 Primary antibodies for Immunofluorescence staining 
Name of antibody Cat.Number Reactivity with Dilution 
SSEA4 Santa cruz 21704 mouse 1:100 
Oct3/4 Santa crut 5279 mouse 1:100 
Oct4 Santa cruz 9081 rabbit 1:100 
Vimentin Abcam 8545 rabbit 1:500 
Nestin N1602 rabbit 1:200 
Cytokeratin18 Abcam 355395 mouse 1:200 
 
5.1.3. Second antibodies 
Name of antibody Cat.Number Reactivity with Dilution 
FITC Sigma F0257 mouse 1:400 
Alexaflour 488 Invitrogen mouse 1:1000 
Cy2 IR67229 mouse 1:400 
TRITC Sigma T5268 rabbit 1:400 
Aleaxfluor 546 Invitrogen rabbit 1:1000 
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